CN101297965B - 胸腺肽β4在制备防治支气管哮喘药物中的应用 - Google Patents
胸腺肽β4在制备防治支气管哮喘药物中的应用 Download PDFInfo
- Publication number
- CN101297965B CN101297965B CN2008100625337A CN200810062533A CN101297965B CN 101297965 B CN101297965 B CN 101297965B CN 2008100625337 A CN2008100625337 A CN 2008100625337A CN 200810062533 A CN200810062533 A CN 200810062533A CN 101297965 B CN101297965 B CN 101297965B
- Authority
- CN
- China
- Prior art keywords
- thymosin
- asthma
- group
- beta4
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 96
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 12
- 230000002992 thymic effect Effects 0.000 title abstract 5
- 210000004072 lung Anatomy 0.000 claims abstract description 31
- 238000009423 ventilation Methods 0.000 claims abstract description 19
- 108010002616 Interleukin-5 Proteins 0.000 claims abstract description 18
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 11
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 101710145873 Thymosin beta Proteins 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000006870 function Effects 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 6
- 208000000884 Airway Obstruction Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000004241 Th2 cell Anatomy 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000035565 breathing frequency Effects 0.000 abstract description 2
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 238000007877 drug screening Methods 0.000 abstract 1
- 210000003714 granulocyte Anatomy 0.000 abstract 1
- 230000004198 lung function level Effects 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 31
- 229960003957 dexamethasone Drugs 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 22
- 102100035000 Thymosin beta-4 Human genes 0.000 description 21
- 108010079996 thymosin beta(4) Proteins 0.000 description 21
- 102000000743 Interleukin-5 Human genes 0.000 description 16
- 206010030113 Oedema Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108010058846 Ovalbumin Proteins 0.000 description 13
- 210000000222 eosinocyte Anatomy 0.000 description 13
- 229940092253 ovalbumin Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 206010070834 Sensitisation Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000008313 sensitization Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 238000001764 infiltration Methods 0.000 description 10
- 108010046075 Thymosin Proteins 0.000 description 9
- 102000007501 Thymosin Human genes 0.000 description 9
- 210000000621 bronchi Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 230000036391 respiratory frequency Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009325 pulmonary function Effects 0.000 description 4
- 208000037816 tissue injury Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 101000644420 Aplysia californica Thymosin beta Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000007875 Femur Head Necrosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 101710185318 Thymic factor Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229920006280 packaging film Polymers 0.000 description 1
- 239000012785 packaging film Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108700016958 thymosin fraction 5 Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
病理分级 | 血管、支气管周围嗜酸性粒细胞浸润 | 水肿 | 气道上皮损伤 |
0分 | 正常 | 正常 | 正常 |
1分 | 轻度细胞浸润无组织病理改变 | 轻度弥漫性水肿 | 轻度细胞缺失 |
2分 | 轻至中度细胞浸润轻度组织损伤 | 中度肺泡、支气管水肿 | 轻度细胞缺失 |
3分 | 中度细胞浸润轻度组织损伤 | 区域或局灶性水肿 | 中度细胞缺失 |
4分 | 中至高度细胞浸润明显组织损伤 | 明显水肿 | 中度细胞缺失 |
5分 | 高度细胞浸润显著组织损伤 | 类肺炎样水肿 | 上皮细胞化生粘液细胞增生 |
组别 | EOS总数(×107) | 白细胞总数(×107) | EOS所占百分比(%) |
胸腺肽β4高剂量组 | 1.581±0.51 | 44.92±3.98 | 3.55±1.19*″# |
胸腺肽β4中剂量组 | 11.83±1.60 | 95.80±3.76 | 12.39±1.98*″# |
胸腺肽β4低剂量组 | 18.18±2.37 | 97.48±3.0 | 18.63±2.22*″# |
***组 | 0.92±0.18 | 41.58±5.91 | 2.22±0.37*″ |
正常对照组 | 0.11±0.03 | 25.91±2.73 | 0.44±0.14 |
哮喘模型组 | 35.52±3.09 | 100.27±10.42 | 35.85±5.35* |
组别 | 小鼠数量(n) | IL-5的浓度 |
胸腺肽β4高剂量组 | 10 | 16.62±1.51″ |
胸腺肽β4中剂量组 | 10 | 18.80±3.84*# |
胸腺肽β4低剂量组 | 10 | 20.42±4.84*# |
***组 | 10 | 16.60±2.74″ |
正常对照组 | 10 | 16.71±1.27 |
哮喘模型组 | 10 | 20.32±3.38*# |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100625337A CN101297965B (zh) | 2008-06-16 | 2008-06-16 | 胸腺肽β4在制备防治支气管哮喘药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100625337A CN101297965B (zh) | 2008-06-16 | 2008-06-16 | 胸腺肽β4在制备防治支气管哮喘药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101297965A CN101297965A (zh) | 2008-11-05 |
CN101297965B true CN101297965B (zh) | 2011-01-05 |
Family
ID=40078000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100625337A Active CN101297965B (zh) | 2008-06-16 | 2008-06-16 | 胸腺肽β4在制备防治支气管哮喘药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101297965B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110887719A (zh) * | 2019-12-20 | 2020-03-17 | 云南中医药大学 | 一种组织病理学的组织样本的处理方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
WO2000006190A1 (en) * | 1998-07-30 | 2000-02-10 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | THYMOSIN β4 PROMOTES WOUND REPAIR |
WO2005062864A2 (en) * | 2003-12-22 | 2005-07-14 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
CN1644586A (zh) * | 1998-03-28 | 2005-07-27 | 格拉斯哥大学董事会 | 氧化胸腺素β4 |
WO2006076588A1 (en) * | 2005-01-13 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
WO2006138707A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage |
WO2007049905A1 (en) * | 2005-10-24 | 2007-05-03 | Caregen Co., Ltd. | Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same |
-
2008
- 2008-06-16 CN CN2008100625337A patent/CN101297965B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
CN1644586A (zh) * | 1998-03-28 | 2005-07-27 | 格拉斯哥大学董事会 | 氧化胸腺素β4 |
WO2000006190A1 (en) * | 1998-07-30 | 2000-02-10 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | THYMOSIN β4 PROMOTES WOUND REPAIR |
WO2005062864A2 (en) * | 2003-12-22 | 2005-07-14 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
WO2006076588A1 (en) * | 2005-01-13 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
WO2006138707A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage |
WO2007049905A1 (en) * | 2005-10-24 | 2007-05-03 | Caregen Co., Ltd. | Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same |
Also Published As
Publication number | Publication date |
---|---|
CN101297965A (zh) | 2008-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104958319A (zh) | 具有卵巢早衰及围绝经期综合征治疗作用的间充质干细胞及其细胞因子制剂及其制备方法 | |
Kim et al. | Detection of allergen specific antibodies from nasal secretion of allergic rhinitis patients | |
CN109939226B (zh) | 一种大籽蒿花粉变应原浸提物、其浸液及其制备方法 | |
MX2013000804A (es) | Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos. | |
Naji et al. | T helper 17 cells and related cytokines after allergen inhalation challenge in allergic asthmatics | |
CN110426523A (zh) | Aim作为生物标志物在诊断、预后和治疗监测类风湿关节炎中的用途 | |
CN101297965B (zh) | 胸腺肽β4在制备防治支气管哮喘药物中的应用 | |
Saghiv et al. | Long lasting chronic resistive training effects on circulating S-Klotho and IGF-1 | |
CN109939227A (zh) | 一种豚草花粉变应原浸提物、其浸液及其制备方法 | |
CN110201188A (zh) | 一种地肤花粉变应原浸提物、其浸提液及其制备方法 | |
CN103272083A (zh) | 用于预防和/或治疗哮喘的药物组合物、其制备方法及用途 | |
JP7394866B2 (ja) | カナムグラ花粉アレルゲン浸漬抽出物、浸出液及びその調製方法 | |
CN102755633A (zh) | 人重组蛋白pdcd5在治疗自身免疫病中的应用 | |
CN101796937A (zh) | 建立无气道高反应性嗜酸粒细胞性气道炎症小鼠模型的方法 | |
CN111714580A (zh) | 一种麻芩消咳药物在制备抗过敏性哮喘药物中的应用 | |
CN116098124A (zh) | 利用Alt a 1对链格孢霉过敏性哮喘小鼠行皮下特异性免疫治疗模型的建立方法 | |
CN109876087A (zh) | 中草药组合物及其用于制备改善肺功能的用途 | |
Smolej et al. | Physiological variation and population structure of the island of Korčula, Yugoslavia | |
CN110064052A (zh) | 一种英国梧桐花粉变应原浸提物、其浸液及其制备方法 | |
CN103173404A (zh) | 一种妊娠期高血压疾病小鼠模型的建立方法 | |
CN117106024B (zh) | 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用 | |
CN101496904B (zh) | 天花粉蛋白诱导的小鼠过敏性哮喘疾病模型 | |
CN110078803B (zh) | 一种洋白蜡花粉变应原浸提物、其浸液及其制备方法 | |
Widianita et al. | Comparison of Death Rates between COVID-19 Patients with Type 2 Diabetes Mellitus and without Type 2 Diabetes Mellitus | |
CN107812184A (zh) | 一种变应原特异性免疫治疗哮喘模型的建立方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG SUPOR SOUTHOCEAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHEJIANG TRADITIONAL CHINESE MEDICINE RESEARCH INSTITUTE Effective date: 20130710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310007 HANGZHOU, ZHEJIANG PROVINCE TO: 310017 HANGZHOU, ZHEJIANG PROVINCE |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081105 Assignee: ZHEJIANG SUPOR SOUTHOCEAN PHARMACEUTICAL CO., LTD. Assignor: Zhejiang Traditional Chinese Medicine Research Institute Contract record no.: 2013330000177 Denomination of invention: Applications of thymic peptide beta4 in preparing medicament for preventing and treating bronchial asthma Granted publication date: 20110105 License type: Exclusive License Record date: 20130607 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130710 Address after: 310017, 105, seven Fort Road, Jianggan District, Zhejiang, Hangzhou Patentee after: ZHEJIANG SUPOR SOUTHOCEAN PHARMACEUTICAL CO., LTD. Address before: 310007 No. 132 Tianmu Mountain Road, Hangzhou, Zhejiang, Xihu District Patentee before: Zhejiang Traditional Chinese Medicine Research Institute |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170609 Address after: 311200, Zhejiang, Hangzhou province Hangzhou large Jiangdong industrial agglomeration, No. 829 Fu Hang Road Patentee after: Hangzhou SUPOR Nanyang Pharmaceutical Co., Ltd. Address before: 310017, 105, seven Fort Road, Jianggan District, Zhejiang, Hangzhou Patentee before: ZHEJIANG SUPOR SOUTHOCEAN PHARMACEUTICAL CO., LTD. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 310000 No. 829, changfuhang Road, Qianjin Street, Qiantang District, Hangzhou City, Zhejiang Province Patentee after: Zhejiang sukean Pharmaceutical Co.,Ltd. Address before: No.829, changfuhang Road, dajiangdong Industrial Cluster District, Hangzhou, Zhejiang 311200 Patentee before: HANGZHOU SUPOR SOUTH OCEAN PHARMACEUTICAL CO.,LTD. |
|
CP03 | Change of name, title or address |